News

Shares of Carvana Co (NYSE:CVNA) are sinking this morning, last seen down 4.7% at $7.68 after a report from the Wall Street Journal quoted an analyst speculating that the used car retailer will run out of cash within a year. Carvana's…
Read More...

U.S. stock futures moved higher on Tuesday morning ahead of a highly anticipated inflation print.Futures tied to the S&P 500 (^GSPC) advanced by at least 0.4% in premarket trading, while futures on the the Dow Jones Industrial…
Read More...

What happened Shares of Twist Bioscience (TWST -10.22%) were crashing this week, plunging 37.2% as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The steep decline came after Scorpion…
Read More...

Spooked in large part by rising bond yields, investors continued to dump stocks last week, extending early-year losses that have taken many off guard with their speed and severity. Once again, tech shares were at the forefront.…
Read More...

Roblox (NYSE:RBLX), a gaming-platform operator, is slated to report its fourth-quarter and full-year 2021 results after the market close on Tuesday, Feb. 15. An analyst conference call is…
Read More...

Stock futures opened lower after another slide in equity markets during the regular trading day, with investors rotating further away from growth and technology stocks that had outperformed early on during the pandemic. Earlier, the…
Read More...

Text size It has been a bumpy week on Wall Street. Ed…
Read More...

2022 has gotten off to a rough start, especially for richly valued high-growth tech stocks. Even semiconductor stocks, which are coming off a banner year in 2021 thanks to the chip shortage, are…
Read More...

It's shaping up to be a dismal year for initial public offerings on U.S. markets in 2022, with the number of IPOs plunging an estimated 78% from the year-ago quarter to a total of 90 — the majority of which were technology and…
Read More...

Entrada Therapeutics (TRDA) inked a $250 million deal with Vertex Pharmaceuticals (VRTX) to develop a muscular dystrophy drug, and the biotech stock surged. X Under the terms of the deal, Vertex will pay Entrada $224 million in…
Read More...